Analysts’ Recent Ratings Updates for Pfizer (PFE)

A number of research firms have changed their ratings and price targets for Pfizer (NYSE: PFE):

  • 4/19/2022 – Pfizer was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
  • 4/11/2022 – Pfizer was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
  • 4/6/2022 – Pfizer is now covered by analysts at Morgan Stanley. They set an “equal weight” rating and a $55.00 price target on the stock.
  • 4/5/2022 – Pfizer had its price target raised by analysts at Citigroup Inc. from $46.00 to $57.00. They now have a “neutral” rating on the stock.
  • 3/31/2022 – Pfizer is now covered by analysts at StockNews.com. They set a “strong-buy” rating on the stock.
  • 2/22/2022 – Pfizer was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.

Shares of PFE traded down $0.67 during trading hours on Thursday, reaching $49.08. The stock had a trading volume of 737,272 shares, compared to its average volume of 32,502,834. Pfizer Inc. has a 12 month low of $37.96 and a 12 month high of $61.71. The stock has a market capitalization of $277.19 billion, a PE ratio of 12.75, a PEG ratio of 0.77 and a beta of 0.77. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.19 and a current ratio of 1.40. The company’s 50-day moving average is $50.91 and its two-hundred day moving average is $51.03.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings results on Tuesday, February 8th. The biopharmaceutical company reported $1.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.23. The company had revenue of $23.84 billion during the quarter, compared to analysts’ expectations of $24.20 billion. Pfizer had a return on equity of 34.53% and a net margin of 26.97%. Pfizer’s revenue was up 104.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.42 EPS. Equities analysts anticipate that Pfizer Inc. will post 7.28 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Ibex Wealth Advisors acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $26,000. Core Alternative Capital acquired a new position in Pfizer during the 3rd quarter valued at about $30,000. Econ Financial Services Corp bought a new position in shares of Pfizer in the fourth quarter valued at approximately $31,000. PYA Waltman Capital LLC purchased a new position in Pfizer in the fourth quarter valued at approximately $31,000. Finally, Rinkey Investments purchased a new position in Pfizer in the fourth quarter valued at approximately $32,000. 64.96% of the stock is owned by institutional investors and hedge funds.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Receive News & Ratings for Pfizer Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc and related companies with MarketBeat.com's FREE daily email newsletter.